Marker Therapeutics Inc (MRKR): Phantom ? ...... “Interim results from...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	13
Posts	1546
Boards Moderated	0
Alias Born	06/14/2018

microcapbiotech

Re: None

Tuesday, 11/22/2022 2:13:56 PM

Tuesday, November 22, 2022 2:13:56 PM

Phantom ? ......
“Interim results from the TACTOPS study PRESENTED at ASCO in 2020" ... that was MT-401, not MT-601.

"Marker intends to initiate a multicenter Phase 1 trial for the treatment of patients with locally advanced unresectable or metastatic pancreatic cancer in combination with front-line chemotherapy in 2023." ........ QUESTION?
Was the Baylor TACTOPS study also done with "in combination with front-line chemotherapy"?
I don't think so, https://clinicaltrials.gov/ct2/show/NCT03192462, "or patients who are not eligible for or have elected not to receive standard of care chemotherapy".

If not, why set it up this way now?
Why not MT-601 as a stand alone treatment?
Do they even know how chemotherapy will affect MT-601 efficiency? good or bad?
Will the side affects of chemotherapy now going to tacked on as side affects of MT-601?